A Clinical Learning Guide — Four-Hit Pathogenesis, Targeted Therapy, and Emerging Agents
Andrew Bland, MD, MBA, MS
IgA nephropathy represents the most common primary kidney disease worldwide, though its prevalence varies significantly by geography and ethnicity. The disease predominantly affects young adults, with men more commonly affected than women in a 2:1 ratio.
The hallmark is deposition of IgA-containing immune complexes in the glomerular mesangium. These deposits trigger inflammatory cascades that can lead to progressive kidney scarring and eventual kidney failure in approximately 30–40% of patients over 20 years.
Begins in gut-associated lymphoid tissue (Peyer's patches). Environmental triggers, genetic factors, or infections stimulate production of galactose-deficient IgA1 antibodies lacking important sugar modifications for proper clearance.
The immune system recognizes abnormal IgA as foreign, producing anti-glycan autoantibodies that specifically target the galactose-deficient regions. Creates an autoimmune response against the body's own antibodies.
Abnormal IgA + autoantibodies form circulating immune complexes with altered size and charge properties that increase their likelihood of depositing in kidneys.
Immune complexes deposit in glomerular mesangium, activating complement pathways, triggering inflammatory cell infiltration, and stimulating fibroblast proliferation leading to progressive scarring.
| Pattern | Frequency | Description |
|---|---|---|
| Classic (synpharyngitic hematuria) | 40% | Gross hematuria within 1–3 days of respiratory infection; "tea-colored" urine |
| Asymptomatic urinary abnormalities | 30% | Microscopic hematuria and proteinuria discovered incidentally |
| Nephrotic/Nephritic syndrome | 20% | Proteinuria >3.5 g/day, hypoalbuminemia, edema, hypertension |
| Acute kidney injury | 10% | Rapid GFR decline, often with crescentic GN on biopsy |
| Risk Level | Proteinuria | Recommended Approach | Monitoring |
|---|---|---|---|
| Low Risk | <1 g/day | ACE-I/ARB optimization | Annual assessment |
| Moderate Risk | 1–3 g/day | TARPEYO + ACE-I/ARB | 3–6 month intervals |
| High Risk | >3 g/day | Sparsentan or combination | Monthly initially |
| Very High Risk | >5 g/day + declining eGFR | Combination therapy + specialist referral | Weekly initially |
All patients should receive optimized RAS inhibition unless contraindicated. Maximize ACE-I or ARB dosing to the highest tolerated level. Target BP <130/80 mmHg.
Sibeprenlimab: Phase 3 VISIONARY trial showed 51.2% proteinuria reduction with excellent safety. Subcutaneous administration every 4 weeks. Represents the highest efficacy demonstrated for any IgAN therapy with disease-modifying potential.
Presentation: 28-year-old with 2.4 g/day proteinuria, eGFR 85, moderate histologic changes.
Treatment: TARPEYO after optimizing ACE-I therapy. Result: 35% proteinuria reduction at 9 months, stable kidney function.
Key lesson: Risk stratification guides treatment intensity; sequential therapy allows escalation if needed.
Presentation: 35-year-old male, 4.2 g/day proteinuria, eGFR decline 90 to 65 over 6 months, crescentic lesions.
Treatment: Sparsentan initiated with plans for combination therapy if inadequate response.
Key lesson: Rapidly progressive disease requires immediate intensive intervention with highest-efficacy agent.
Scenario: 26-year-old female with stable IgAN planning pregnancy.
Key lesson: Most novel therapies are contraindicated in pregnancy. Optimize supportive care with pregnancy-compatible agents; close obstetric-nephrology collaboration essential.
Q1: 25-year-old female with IgAN and 2.8 g/day proteinuria is planning pregnancy in 6 months. Which approach is most appropriate?
A) Start sparsentan B) Initiate TARPEYO C) Stop ACE-I once pregnant; plan pregnancy-compatible management D) Begin combination therapy
Answer: C — Pregnancy planning requires compatible agents; most novel therapies are contraindicated.
Q2: Which mechanism best explains sparsentan's superior efficacy compared to standard ACE-I therapy?
A) More potent angiotensin receptor blockade B) Dual pathway targeting with synergistic effects C) Selective complement inhibition D) Direct anti-inflammatory properties
Answer: B — Dual endothelin and angiotensin receptor blockade provides synergistic benefits.
Q3: A patient on iptacopan develops recurrent bacterial infections. Most likely explanation?
A) Drug intolerance B) Complement inhibition increasing infection risk; enhance monitoring and vaccination C) Unrelated coincidence D) Indication for combination with antibiotics
Answer: B — Complement inhibition increases infection risk requiring enhanced surveillance.
IgA nephropathy therapy has transformed from supportive care to targeted intervention addressing specific disease mechanisms. This represents one of the most significant advances in nephrology over the past decade.
© Urine Nephrology Now — Clinical Mastery Series